Followers | 261 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
![](https://investorshub.advfn.com/uicon/45965.png?cb=1637315758)
Friday, March 04, 2011 11:22:24 AM
The test demonstrated several things. Since there is a question of penetration of the nanomicelle to heavily congested respiratory areas, one thing demonstrated is that the injectable FluCide does deliver to infected regions from the circulatory system. Secondly, in life threatening cases of influenza, the mice were gonna die, the injection salvaged 50% of the mice where tamiflu saved none. Third, under therapeutic standards of delivery at the time, FluCide delivered a 15x reduction of viral load as compared to tamiflu.
Yes, in clinical use, method of delivery is important and relevant. Tamiflu now is approved in an intravenous form in order to bring the drug levels in the patient more quickly to therapeutic levels in cases where that is needed or when oral delivery is impractical. And, yes it would be interesting to see the results of a challenge between the two injectable forms. However, given the nature of TamiFlu, a highly toxic neuraminidase inhibitor that has a very narrow dosage range between therapeutic levels and levels when toxic outcomes become evident, I would doubt the results would be much different.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM